bioRxiv Science⌕ Search

Biology subjects

McCoy, M.

Publications and source records attributed to McCoy, M..

11 recordsLinked to original sources

Hidden State Genomics: Graph-Based Analysis of Sparse Auto-Encoder Feature Activity in Genomic Language Models

Pre-trained genomic language model (gLM) representations have been anticipated to enable enhanced deep learning predictions on several genomics tasks, but current benchmarking has led to questions over what they actually encode. We studied this with mechanistic interpretability on InstaDeeps Nucleotide Transformer v2 (500M), training sparse autoencoders across all 24 encoder layers to probe latent features. Correlation-based annotation against reference regulatory tracks was inconsistent across layers and insufficient for causal interpretation. We therefore built typed sequence-to-feature knowledge graphs to explore the SAE feature space and compared cisplatin-binding versus non-binding genomic DNA sequence communities by PageRank centrality, validating candidate features with decoder-based interventions and a CNN binding classifier. Interventions showed asymmetric effects: suppressive features could collapse predictive signal, while binding-associated features shifted predictions cumulatively with the presence of other binding-associated signals. Dependency maps further indicated strong local feature sensitivity within sequences. Together, these results provide evidence that gLM representations encode highly granular sequence syntax and conservation patterns, aligning more strongly with tightly coupled molecular interactions and local biophysical constraints than with complex, distributed regulatory logic. Within the scope of our intervention setting, this pattern is consistent with stronger performance on selected molecular tasks and weaker performance on broader regulatory inference, motivating scalable methods for causal feature annotation.

bioinformatics↗

Early ingestive experience with a high-fat diet tunes satiation and nutrient-specific appetitive behaviors

Overconsumption of foods rich in fats, sugars, and calories is a major contributing factor to increased risk for cardiometabolic disease. Ingestive experience with these foods can begin early in children, yet there is limited understanding of the impact of early life nutrition on the development of vagal afferent neurons necessary for coordinating appetitive and satiating behaviors. To address this gap, mice reared on a chow diet (control) were compared to those reared on a high-fat diet (HFDEARLY). We demonstrate that the vagally-mediated satiation response to cholecystokinin (CCK) does not mature until adolescence in chow-reared mice. However, HFDEARLY exposure triggers a precocious maturation of this response, accompanied by transcriptomic changes in the nodose ganglion. Durable changes in appetitive behaviors were also evident in adult HFDEARLY mice, which consumed more lipid than control mice. Behavioral analyses point to alterations in orosensory processing and enhanced appetition in adult HFDEARLY mice. Furthermore, female HFDEARLY mice showed a selective increase in consumption of a calorie-dense liquid diet in adulthood, accompanied by changes in body composition, suggesting a lasting, sex-specific vulnerability to overconsumption of palatable, energy-dense foods. Together, these results establish nutrient exposure as a significant contributor to vagal circuit maturation and function.

animal behavior and cognition↗

A Computational Workflow for Structure-Guided Design of Potent and Selective Kinase Peptide Substrates

Kinases are pivotal cell signaling regulators and prominent drug targets. Short peptide substrates are widely used in kinase activity assays essential for investigating kinase biology and drug discovery. However, designing substrates with high activity and specificity remains challenging. Here, we present Subtimizer (substrate optimizer), a streamlined computational pipeline for structure-guided kinase peptide substrate design using AlphaFold-Multimer for structure modeling, ProteinMPNN for sequence design, and AlphaFold2-based interface evaluation. Applied to five kinases, four showed substantially improved activity (up to 350%) with designed peptides. Kinetic analyses revealed >2-fold reductions in Michaelis constant (Km), indicating improved enzyme-substrate affinity. Two designed peptides exhibited >5-fold improvement in selectivity. This study demonstrates AI-driven structure-guided protein design as an effective approach for developing potent and selective kinase substrates, facilitating assay development for drug discovery and functional investigation of the kinome.

bioinformatics↗

Select azo compounds post-translationally modulate HTRA1 abundance and activity potentially through interactions at the trimer interface

High-temperature requirement protein A1 (HTRA1) is a secreted serine protease with diverse substrates, including extracellular matrix proteins, proteins involved in amyloid deposition, and growth factors. Accordingly, HTRA1 has been implicated in a variety of neurodegenerative diseases including a leading cause of blindness in the elderly, age-related macular degeneration (AMD). In fact, genome wide association studies have identified that the 10q26 locus which contains HTRA1 confers the strongest genetic risk factor for AMD. A recent study has suggested that AMD-associated risk alleles in HTRA1 correlate with a significant age-related defect in HTRA1 synthesis in the retinal pigmented epithelium (RPE) within the eye, possibly accounting for AMD susceptibility. Thus, we sought to identify small molecule enhancers of HTRA1 transcription and/or protein abundance using an unbiased high-throughput screening approach. To accomplish this goal, we used CRISPR/Sp.Cas9 engineering to introduce an 11 amino acid luminescent peptide tag (HiBiT) onto the C-terminus of HTRA1 in immortalized ARPE-19 cells. Editing was very efficient ([~]88%), verified by genomic DNA analysis, short interfering RNA (siRNA), and HiBiT blotting. Nineteen-hundred and twenty compounds from two libraries were screened. An azo compound with reported anti-amyloidogenic and cardioprotective activity, Chicago Sky Blue 6B (CSB), was identified as an enhancer of endogenous HTRA1 secretion (2.0 {+/-} 0.3 fold) and intracellular levels (1.7 {+/-} 0.2 fold). These results were counter-screened using HiBiT complement factor H (CFH) edited ARPE-19 cells, verified using HiBiT blotting, and were not due to HTRA1 transcriptional changes. Importantly, serine hydrolase activity-based protein profiling (SH-ABPP) demonstrated that CSB does not affect HTRA1s specific activity. However, interestingly, in follow-up studies, Congo Red, another azo compound structurally similar to CSB, also substantially increased intracellular HTRA1 levels (up to 3.6 {+/-} 0.3 fold) but was found to significantly impair HTRA1 enzymatic reactivity (0.45 {+/-} 0.07 fold). Computational modeling of potential azo dye interaction with HTRA1 suggests that CSB and Congo Red can bind to the non-catalytic face of the trimer interface but with different orientation tolerances and interaction energies. These studies identify select azo dyes as HTRA1 chemical probes which may serve as starting points for future HTRA1-centered small molecule therapeutics.

biochemistry↗

Miro1 knockout inhibits mouse breast cancer tumorigenesis

Miro1 is a mitochondrial outer membrane protein that regulates mitochondrial and peroxisome trafficking, endoplasmic reticulum (ER) association, and mitophagy. Prior studies suggest a role for Miro1 in cell migration and proliferation in both normal and tumor cells. High Miro1 expression is associated with poor overall survival in breast cancer patients. To investigate the role of Miro1 in breast cancer tumorigenesis and metastasis, we established stable Miro1 knockdown (KD) in MDA-MB-231 human triple-negative breast cancer cells using shRNA. Miro1 KD significantly impaired cell proliferation, migration, and invasion in vitro. When implanted into the mammary fat pad of SCID mice, MDA-MB-231 cells formed tumors, whereas Miro1 KD cells showed markedly reduced tumorigenesis. Additionally, we generated a novel transgenic mouse model with inducible, tissue-specific Miro1 deletion in mammary epithelial cells, alongside polyomavirus middle T-antigen (PyVMT) oncogene activation. In this model, wild-type (WT) mice formed tumors at all mammary gland sites, with frequent lung metastases. However, Miro1-deficient mice failed to develop tumors, while heterozygous mice exhibited reduced tumor growth and metastasis. Additionally, these findings identify Miro1 as a key regulator of breast cancer onset and metastatic potential, positioning it as a potential biomarker and therapeutic target.

cancer biology↗

Benchmarking and optimizing Perturb-seq in differentiating human pluripotent stem cells

Perturb-seq is a powerful approach to systematically assess how genes and enhancers impact the molecular and cellular pathways of development and disease. However, technical challenges have limited its application in stem cell-based systems. Here, we benchmarked Perturb-seq across multiple CRISPRi modalities, on diverse genomic targets, in multiple human pluripotent stem cells, during directed differentiation to multiple lineages, and across multiple sgRNA delivery systems. To ensure cost-effective production of large-scale Perturb-seq datasets as part of the Impact of Genomic Variants on Function (IGVF) consortium, our optimized protocol dynamically assesses experiment quality across the weeks-long procedure. Our analysis of 1,996,260 sequenced cells across benchmarking datasets reveals shared regulatory networks linking disease-associated enhancers and genes with downstream targets during cardiomyocyte differentiation. This study establishes open tools and resources for interrogating genome function during stem cell differentiation.

genomics↗

LEA_4 motifs function alone and in conjunction with synergistic cosolutes to protect a labile enzyme during desiccation

Organisms from all kingdoms of life depend on Late Embryogenesis Abundant (LEA) proteins to survive desiccation. LEA proteins are divided into broad families distinguished by the presence of family-specific motif sequences. The LEA_4 family, characterized by eleven-residue motifs, plays a crucial role in the desiccation tolerance of numerous species. However, the role of these motifs in the function of LEA_4 proteins is unclear, with some studies finding that they recapitulate the function of full-length LEA_4 proteins in vivo, and other studies finding the opposite result. In this study, we characterize the ability of LEA_4 motifs to protect a desiccation-sensitive enzyme, citrate synthase, from loss of function during desiccation. We show here that LEA_4 motifs not only prevent the loss of function of citrate synthase during desiccation, but also that they can do so more robustly via synergistically interactions with cosolutes. Our analysis further suggests that cosolutes induce synergy with LEA_4 motifs in a manner that correlates with transfer free energy (TFE). This research advances our understanding of LEA_4 proteins by demonstrating that during desiccation their motifs can protect specific clients to varying degrees and that their protective capacity is modulated by their chemical environment. Our findings extend beyond the realm of desiccation tolerance, offering insights into the interplay between IDPs and cosolutes. By investigating the function of LEA_4 motifs, we highlight broader strategies for understanding protein stability and function.

biochemistry↗

Synergistic and antagonistic drug-drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines

Acute myeloid leukemia (AML) is the most prevalent type of leukemia in adults. Despite advancements in medicine, the standard treatment that utilizes a combination of cytarabine and daunorubicin for AML has remained the same for decades. Combination drug therapies are proven to be an effective way to achieve targeted efficacy while minimizing drug dosage along with the unintended side effects. However, a systematic survey of synergistic potential of drug-drug interactions in the context of AML pathology is currently lacking. Here we examine the interactions between 15 frequently used cancer drugs across distinct AML cell lines and demonstrate that synergistic and antagonistic drug-drug interactions are widespread but not conserved across these cell lines. Notably, enasidenib (AG-221) and venetoclax (ABT-199), recently approved anticancer agents, exhibited the highest counts of synergistic interactions and the fewest antagonistic ones. In contrast, 6-Thioguanine (6-TG), a purine analog, was involved in the highest number of antagonistic interactions. The interactions we report here cannot be attributed solely to the inherent synergistic or antagonistic natures of these three drugs, as each drug we examined was involved in several synergistic or antagonistic interactions in the cell lines we tested. Moreover, we observed that these drug-drug interactions are not conserved across cell lines, suggesting that the success of combination therapies might vary depending on AML genotypes. For instance, we found that a single mutation in the TF1 cell line could dramatically alter drug-drug interactions, even turning synergistic interactions into antagonistic ones, as seen with AG-221 and cladribine A (2CdA). Our findings provide a preclinical survey of the potential synergistic effects revealing the complexity of the problem in vitro. However, the exploitable synergistic regimes in clinical scenarios remain to be explored. We anticipate these results to be an insightful guideline for future clinical studies, aiming to refine chemotherapy regimens and ultimately enhance patient outcomes.

cancer biology↗

Ontogeny of Vagal Sensory Cell Types and Trophic Factor Sensitivity

Vagal sensory neurons located in the nodose ganglion provide a direct line of communication from the gut to the brain. Information, such as stomach stretch or the presence of ingested nutrients in the intestine, is conveyed to the caudal medulla via specialized cell types that express unique marker genes. Here, we leverage vagal cell type marker genes identified in adult mice to determine when specialized vagal subtypes arise developmentally, as well as the factors that shape their growth and target innervation. Initial sequencing and pathway analysis comparing early postnatal to adult nodose ganglia identified an enrichment of differentially expressed genes (DEGs) related to axon growth and guidance, synaptic strengthening, and DEGs downstream of brain derived neurotrophic factor (BDNF). Subsequent experiments performed to screen for trophic factor sensitivity revealed that both BDNF and glial cell derived neurotrophic factor (GDNF) robustly stimulate neurite outgrowth from early postnatal nodose ganglion explants in vitro. Anatomical examination of whole-body trophic factor expression in perinatal mice revealed that BDNF is expressed by neurons of the nodose ganglion itself, while GDNF is expressed by developing intestinal smooth muscle cells. Thus, BDNF may support vagal neurons as a locally derived trophic factor, while GDNF may act as a target derived trophic factor supporting the growth of vagal sensory processes at distal innervation sites in the gut. Consistent with this, expression of the GDNF receptor, Gfra1, was enriched in vagal afferent cell types that project to the gastrointestinal tract. The BDNF receptor, Ntrk2, was expressed by the majority vagal sensory neurons, irrespective of cell type. Lastly, spatial mapping of genetic markers in the nodose ganglion demonstrates that defined vagal cell types begin to emerge as early as embryonic day 13, even as sensory neurons continue to grow to reach gastrointestinal targets. Despite the early onset of expression for some cell type marker genes, expression patterns of many individual cell type markers appear largely immature in prenatal life and mature considerably by the end of the first postnatal week. Together, the data support a role for GDNF in stimulating vagal sensory growth to gastrointestinal targets and establish a prolonged perinatal timeline for vagal sensory cell type maturation.

neuroscience↗

Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition

Oncogenic mutations in the kinase domain of the B-Raf protein have long been associated with cancers involving the MAPK pathway. One constitutive MAPK activating mutation in B-Raf, the V600E (valine to glutamate) replacement occurring adjacent to a site of threonine phosphorylation (T599) occurs in many types of cancer, and in a large percentage of certain cancers, such as melanoma. Because ATP binding activity and the V600E mutation are both known to alter the physical behavior of the activation loop in the B-Raf ATP binding domain, this system is especially amenable to comparative analyses of molecular dynamics simulations modeling various genetic and drug class variants. Here, we employ machine learning enabled identification of functionally conserved protein dynamics to compare how the binding interactions of four B-Raf inhibitors impact the functional loop dynamics controlling ATP activation. We demonstrate that drug development targeting B-Raf has progressively moved towards ATP competitive inhibitors that demonstrate less tendency to mimic the functionally conserved dynamic changes associated with ATP activation and leading to the side effect of hyperactivation (i.e. inducing MAPK activation in non-tumorous cells in the absence of secondary mutation). We compare the functional dynamic impacts of V600E and other sensitizing and drug resistance causing mutations in the regulatory loops of B-Raf, confirming sites of low mutational tolerance in these regions. Lastly, we investigate V600E sensitivity of B-Raf loop dynamics in an evolutionary context, demonstrating that while sensitivity has an ancient origin with primitive eukaryotes, it was also secondarily increased during early jawed vertebrate evolution.

biophysics↗

Clingen Cancer Somatic Working Group: standardizing and democratizing access to cancer molecular diagnostic data to drive translational research

A growing number of academic and community clinics are conducting genomic testing to inform treatment decisions for cancer patients (1). In the last 3-5 years, there has been a rapid increase in clinical use of next generation sequencing (NGS) based cancer molecular diagnostic (MolDx) testing (2). The increasing availability and decreasing cost of tumor genomic profiling means that physicians can now make treatment decisions armed with patient-specific genetic information. Accumulating research in the cancer biology field indicates that there is significant potential to improve cancer patient outcomes by effectively leveraging this rich source of genomic data in treatment planning (3). To achieve truly personalized medicine in oncology, it is critical to catalog cancer sequence variants from MolDx testing for their clinical relevance along with treatment information and patient outcomes, and to do so in a way that supports large-scale data aggregation and new hypothesis generation. One critical challenge to encoding variant data is adopting a standard of annotation of those variants that are clinically actionable. Through the NIH-funded Clinical Genome Resource (ClinGen) (4), in collaboration with NLMs ClinVar database and >50 academic and industry based cancer research organizations, we developed the Minimal Variant Level Data (MVLD) framework to standardize reporting and interpretation of drug associated alterations (5). We are currently involved in collaborative efforts to align the MVLD framework with parallel, complementary sequence variants interpretation clinical guidelines from the Association of Molecular Pathologists (AMP) for clinical labs (6). In order to truly democratize access to MolDx data for care and research needs, these standards must be harmonized to support sharing of clinical cancer variants. Here we describe the processes and methods developed within the ClinGens Somatic WG in collaboration with over 60 cancer care and research organizations as well as CLIA-certified, CAP-accredited clinical testing labs to develop standards for cancer variant interpretation and sharing.

bioinformatics↗